SEC Form 4 · accession 0001193125-26-393274
AN2 Therapeutics, Inc. · ANTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron C. Trenor III
Officer — Chief Medical Officer
Period of report
Sep 15, 2026
Accepted (ET)
Sep 16, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001880438
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | A | 116,667 | $0.00 | A | 116,667 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to by)F2 | $5.36 | Sep 15, 2026 | A | 233,333 | A | — | Sep 14, 2036 | Common Stock | 233,333 | 233,333 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") which vest as follows: 10,400 RSUs vest on January 1, 2027, prorated from August 24, 2026, the vesting start date, and the remaining RSUs vest in equal annual installments on each January 1, 2028, January 1, 2029 and January 1, 2030, subject to the Reporting Person's continuous service through each applicable vesting date.
- F2The shares subject to the stock option vest as follows: 25% of the shares vest on August 24, 2027 and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.